Merck & Co Inc

NYSE:MRK   3:59:58 PM EDT
73.04
+1.00 (+1.39%)
5:22:50 PM EDT: $73.14 +0.10 (+0.14%)
Products

Merck And Ridgeback Biotherapeutics Announce Initiation Of Pivotal Phase 3 Move-Ahead Study Evaluating Molnupiravir For Post-Exposure Prophylaxis Of Covid-19 Infection

Published: 09/01/2021 11:40 GMT
Merck & Co Inc (MRK) - Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 Move-ahead Study Evaluating Molnupiravir for Post-exposure Prophylaxis of Covid-19 Infection.
Merck & Co Inc - Study Now Enrolling Participants Who Live in Same Household As Someone With Symptomatic, Laboratory-confirmed Covid-19.
Merck & Co Inc - Study Now Enrolling Participants Who Live in Same Household As Someone With Symptomatic, Laboratory-confirmed Covid-19.
Merck & Co Inc - Data From Study is Expected in Second Half of 2021.
Merck & Co Inc - Safety and Efficacy of Molnupiravir is Also Currently Being Evaluated in Part 2 of Ongoing Move-out Trial.